Small-cap biotech KalVista to be acquired by Italy's Chiesi; stock hits 5-year high

Shares of rare disease small cap developer KalVista Pharmaceuticals surged almost 40% on Wednesday to their highest level since mid-2021 after the biotech said it would be acquired at a premium by Italian drugmaker Chiesi Group. M&A activity in the rare disease space continues to accelerate, and investors should watch the sector closely for new opportunities, writes Noble Capital Markets.

KalVista shares jumped nearly 39% on the Nasdaq on Wednesday to $26.70 per share, a five-year high, after the company announced plans to be acquired by Chiesi.

A Chiesi subsidiary launched a tender offer to acquire all outstanding stock of the small-cap biotech for $27 per share in cash, representing a 36% premium to KalVista’s 30-day volume-weighted average share price, the companies said in a press release. The deal values KalVista at approximately $1.9 billion.

The companies expect to close the transaction in the third quarter of 2026, subject to regulatory approvals and the tender of a majority of KalVista stock.

KalVista’s portfolio consists of a single asset, EKTERLY, the “first and only” oral on-demand treatment for hereditary angioedema, a rare genetic disorder that causes uncontrolled swelling of the skin, face, abdomen, and throat and can become life-threatening.

The FDA approved EKTERLY for patients aged 12 and older in July. The UK regulator approved the treatment days later, followed by the EU in September.

Before EKTERLY, all approved hereditary angioedema therapies on the market were injectable, the company said. Because attacks are often unpredictable, the need for injections frequently delayed treatment. EKTERLY allows patients to begin treating attacks within 10 minutes.

From the July 7 commercial launch through December 31, KalVista generated $49 million in revenue from EKTERLY, the company reported. Noble described that as an impressive result for a newly launched rare disease therapy. KalVista is also testing the treatment in children as young as two years old.

Analysts at Noble said investors who believe in the long-term prospects of small-cap biotech companies should monitor the market closely for the next opportunities. They said dealmaking in rare diseases is accelerating as larger pharmaceutical companies seek to diversify their businesses.

For Chiesi, which has been steadily expanding its Global Rare Diseases division, the acquisition is not just about adding a product but also about building infrastructure because the deal will significantly expand the Italian company’s presence in the U.S., the analysts added. KalVista said in its press release that Chiesi expects to increase revenue by 67% by 2030 versus 2025 levels, driven in large part by KalVista’s therapy.

KalVista shares have gained 65% year to date. Four Wall Street analysts rate the stock “buy,” while three recommend “hold.” The average target price is $34 per share, implying 26% upside versus the deal price.